Finance Watch: Mega-Rounds Add Up To Another Record Year For Biopharma VC Funding

Maze Therapeutics Closes Latest $100m-Plus Round

 
• By Mandy Jackson and Jung Won Shin
  
Generate a summary of this article
Listen to this article
Beta

Private Company Edition: NVCA and Pitchbook data show pharma and biotech companies raised $37.8bn in venture capital in 2021, up 41% from the record $26.8bn total in 2020. Recent mega-rounds include $190m for Maze and $200m for Alumis, and Sound Bioventures raised a €110m fund.

Finance Watch Private Company
• Source: Shutterstock

Biopharmaceutical company venture capital fundraising in 2021 broke the record set in 2020 back in the third quarter and now that the year is over, Pitchbook and the National Venture Capital Association reported in the latest edition of their quarterly Venture Monitor report on 14 January that 1,198 biopharma companies raised $37.8bn last year – a 41% increase in the dollar amount raised versus 2020, when 1,042 companies raised $26.8bn.

The average size of VC financings also increased from year to year from an average of $25.7m in 2020 to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.